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ABSTRACT
The native Idaho plant Veratrum californicum is known to contain steroidal
alkaloids that function as inhibitors of hedgehog signaling, a pathway utilized for the
growth and differentiation of cells as well as proper tissue development. Veratrum
californicum was originally noticed when pregnant ewes consumed the plant and later
gave birth to lambs with craniofacial mutations such as a cyclopean eyes. These
malformations were caused by the plant’s steroidal alkaloid cyclopamine blocking the
hedgehog signaling pathway. This same pathway is used by more than 20 types of cancer
for multiplication of cells. Additional alkaloids have been found in Veratrum
californicum, which are being studied in order to identify additional hedgehog signaling
inhibitors. There are at least seven compounds detected in extracts that are completely
uncharacterized, twelve with proposed identities, and the six known alkaloids veratrosine,
cycloposine, veratramine, cyclopamine, isorubijervine, and muldamine all within
Veratrum californicum. In this thesis these molecules were extracted together from the
root and rhizome of the plant, and then separated into five fractions using high
performance liquid chromatography. Mass spectrometry analysis identified the presence
of twenty five alkaloids (nine more than literature precedent), and software processing of
the data predicted the molecular formulas for each known, suspected, and unknown
alkaloid. The bioactivity of the raw extract and each fraction was assessed by comparison
to 0.1 µM cyclopamine, and it was found that three fractions suppressed hedgehog
signaling to a greater extent, indicating the presence of bioactive constituents worthy of
vi

further investigation. Five fractions were collected at 2.5 min intervals, beginning at
10.25 min from time of raw extract injection. Fraction 1 was most potent at Hh signal
inhibition, and was determined to contain veratrosine, cycloposine, and an isomer of
each, followed by fractions 2 and 4, which possessed elevated bioactivity, but to a lesser
extent than fraction 1. Fraction 2 was predicted to be comprised of cycloposine, its
isomer, an isomer of veratrosine, tetrahydrojervine, veratramine, dihydrojervine, its
isomer, etioline, and five unknown compounds. Fraction 4 was composed of
cyclopamine, and suspected to contain isomers of veratramine and cyclopamine,
isorubijervine, and muldamine, as well as two unknown alkaloids
.
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CHAPTER ONE: VERATRUM CALIFORNICUM ALKALOIDS
The following chapter was published in the journal Molecules in September 2021.1

Abstract: Veratrum spp. grow throughout the world and are especially prevalent
in high mountain meadows of North America. All parts of Veratrum plants have been
used for the treatment of ailments including injuries, hypertension, and rheumatic pain
since as far back as the 1600s. Of the 17–45 Veratrum spp., Veratrum californicum
alkaloids have been proven to possess favorable medicinal properties associated with
inhibition of hedgehog (Hh) pathway signaling. Aberrant Hh signaling leads to
proliferation of over 20 cancers, including basal cell carcinoma, prostate and colon
among others. Six of the most well-studied V. californicum alkaloids are cyclopamine
(1), veratramine (2), isorubijervine (3), muldamine (4), cycloposine (5), and veratrosine
(6). Recent inspection of the ethanolic extract from V. californicum root and rhizome via
liquid chromatography–mass spectrometry has detected up to five additional alkaloids
that are proposed to be verazine (7), etioline (8), tetrahydrojervine (9), dihydrojervine
(10), 22-keto-26-aminocholesterol (11). For each alkaloid identified or proposed in V.
californicum, this review surveys literature precedents for extraction methods, isolation,
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identification, characterization and bioactivity to guide natural product drug discovery
associated with this medicinal plant.
1. Introduction
The genus Veratrum consists of 17–45 spp., most of which naturally occur in
Asia, and all of them located exclusively in the Northern hemisphere. These perennials
can either be classified as part of the Liliaceae or the Melanthiaceae family.2 Typically,
the species of Veratrum have been classified by their gross morphology, but the wide
variety within the species has led to an absence of defined taxonomy.3 In 2003, Zomlefer
et al. classified Veratrum spp. by examination of their nuclear ribosomal internal
transcribed spacers (ITS).4 This ITS method was correlated to traditional taxonomic
classification by corresponding analysis of flower color and geographical location.4
Table 1.1 lists the geographic region, a corresponding flower image, and the alkaloids
and other relevant active components for representative Veratrum spp. that are pertinent
to the current review. Based on alkaloid composition, the Veratrum spp. that will be
discussed in this review are V. lobelianum, V. grandiflorum, V. oxysepalum, V. maackii,
V. nigrum, V. taliense, V. viride, V. eschscholtzii and V. californicum (Table 1.1).
Chemical structures of V. californicum steroidal alkaloids may be found in Figure 1.1
and are identified by a number in bold font. The structures of additional alkaloids
described in this review may be found in Figure S1.
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Table 1.1.
review.
Species

V. album
var.
lobelianu
m

Flower and geographic region for Veratrum spp. addressed in this

Flower

Region

Alkaloid(s)

Verabenzoamine,
veratroilzigadenin
e, 15-O-(2Methylbutyroyl)ge
Et linoleate,
rmine,
Northern
β-Sitosterol,
veralosinine,
Asia, parts of
resveratrol,
veranigrine, 7,
oxyresveratr
Europe
jervine,
ol
pseudojervine,
rubijervine,
veralosine,
veralosidine

V. album
var.
grandiflor
um

Asia

2

V. album
var.
oxysepalu
m

Parts of
Europe and
northeastern
Asia

2, veratridine,
cevadine

V. maackii

Other
Bioactive Reference
Components

Asia

Resveratrol

Verussurine,
verabenzoamine,
7, isoverazine,
Stilbenes,
verazinine, 23- flavonoids,
methoxycyclopam phenols,
ine 3-O-β-Dglyceride
glucopyranoside,
isoecliptalbine

[5–8]

[3,4,9–18]

[19–25]

[26–28]

4

V. nigrum

Europe and
Asia

V. taliense

Alkaloids
Europe and
including
Asia
isorubijervine and
rubijervine

7, epiverazine, 2

[29–32]

[16–18,33,34]

V. viride
var. viride

North
America

2

[2,35,36]

V. viride
var.
eschscholt
zii

North
America

Isorubijervosine,
pseudojervine, 6

[2,37–40]

V.
californic
um var.
californic
um

North
America

1, 2, 3, 4, 5, 6

[2,41–43]
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Figure 1.1.

Structures of 11 known and proposed alkaloids in Veratrum
californicum.

Interest in the Veratrum genus is attributable to the medicinal and therapeutic
properties of steroidal alkaloids produced by the plants. Over 100 alkaloids have been
identified, mostly from extraction of the root and rhizome, with several of the alkaloids
demonstrating cancer suppression, induction of bradycardia, analgesia, and other effects.2
Bioactive components from Veratrum have been identified within 16 species, but only V.
album, V. viride, and V. nigrum have been thoroughly studied.4 A brief overview of
Veratrum spp. from which researchers have identified bioactive constituents for potential
use as phytotherapeutics is provided. Much of our understanding of Veratrum spp.
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component activity originates from animal or human poisoning associated with accidental
ingestion of plant material. Observations of one-eyed sheep birth defects, low heart rate,
vomiting, diarrhea, and other side effects attributable to Veratrum poisoning have led to
investigations identifying active constituents consisting of alkaloid and non-alkaloid
compounds. To provide a background of instances of Veratrum poisoning that have led to
studies of active components and ultimately alkaloid (and non-alkaloid) identification,
several case studies are included in this review.
1.1. V. album: subspecies V. lobelianum, V. grandiflorum and V. oxysepalum
V. album is a species complex of three subspecies, V. lobelianum, V.
grandiflorum, and V. oxysepalum, sharing the common name white false hellebore.2 This
species is prevalent in northern Eurasia and to a lesser extent may be encountered in
localized outcrops in North America, specifically in northern Alaska.2,3 This plant
complex had been used medicinally for centuries for its emetic properties well before the
cause of this effect was understood. In 1820 V. album became one of the first Veratrum
species analyzed for the presence of steroidal alkaloids. Eventually it was determined that
certain V. album alkaloids induced a hypotensive effect by binding to voltage-gated
sodium channels, causing the channels to remain open. When a neuronal stimulus
occurred, multiple signals were released, because the cell’s ability to repolarize was
inhibited. This property led to increased use of the plant to treat hypertension. With rising
demand, more plants had to be grown, but the supply was unreliable due to slow growth

7
and germination rates as well as chilling requirements. Phytotherapies incorporating V.
album alkaloids were also discontinued due to difficulty in achieving the appropriate
dosing for patients; the difference between toxic and therapeutic doses was about 30%.2
1.1.1. V. lobelianum
V. lobelianum grows in most countries in northern Asia, but is also found less
frequently in parts of Europe.5 In Russia it is called “chemeritsa” and has been used as
part of Russian traditional medicine for hundreds of years. A tincture made from the plant
has been incorporated as an ingredient in ointments that are rubbed onto a patient’s skin
to treat scabies and neuralgic and rheumatic pain. When the roots and rhizomes are boiled
and concentrated, they are applied to the scalp as a treatment for lice. Together, baked
roots, rhizomes, and cream have been an applicant for eczemas. Aqua veratri, commonly
known as Hellebore water, is a dilution of the V. lobelianum tincture used to treat
psoriasis by rubbing the ointment into the scalp of the patient. V. lobelianum has also
been consumed to reduce fever, typhus, and pneumonia. The plant is possibly best known
as an antiparasitic, including its use to combat hypodermatosis in cattle and to induce
emesis in pigs.44
1.1.2. V. grandiflorum
V. grandiflorum, also known as white hellebore4, has a geographical growth
region predominantly in Asia.2,3 Arthritis and gout have been treated using V.
grandiflorum extract, which contains active components including stilbenoid phenol and
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resveratrol, which promote anti-inflammatory and anti-osteoarthritis responses.9 In the
5th century BCE, it was thought that gout was caused by overeating, and thus
Hippocrates recommended consuming large amounts of V. grandiflorum in order to
induce vomiting.11 In the 1800s, a controversial treatment for gout was a tincture made
from a combination of V. grandiflorum, tobacco, foxglove, wild cucumber, and a mix of
other plants for flavor and aroma.12 Resveratrol, the component of red wine that has
gained considerable attention in recent years, was first isolated in 1940 from V.
grandiflorum, a fact that is still evident in its name. Resveratrol has had a long history of
clinical trials utilizing different diets and dosages of oral supplements to most effectively
employ its anti-oxidative, anti-aging, anti-cancer, and cholesterol lowering properties.15,45
1.1.3. V. oxysepalum
The final member of the V. album complex is V. oxysepalum, which primarily
grows in parts of Europe and northeastern Asia.19,20 V. oxysepalum is the most common
member of the V. album complex to be mistaken for an edible plant; when consumed, it
induces poisoning due to the presence and abundance of toxic alkaloids. When V.
oxysepalum is ingested, a person will suffer from vomiting, a drop in blood pressure and
heart rate, and a tingling sensation in their mouth.19 There have been at least seven
situations where V. oxysepalum was confused for an edible wild plant, and upon ingestion
led to accidental poisoning. The first report was associated with gentian wine, which
requires the European Gentiana lutea, a plant that bears remarkable similarity to V.
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oxysepalum.19 In 2004, two men living in Italy consumed a beverage freshly prepared by
a friend, thinking it was made from Gentiana lutea. Within the hour, they experienced
nausea, vomiting, and headaches, and one man had diarrhea. After admittance to the
hospital, both patients were treated with activated charcoal and an anti-emetic and
discharged within 24 h.46 A second, similar incident involving confusion of V.
oxysepalum for G. lutea occurred in 2008.21 A set of four separate cases occurred in the
hills near Ljubljana, Slovenia in the months of April and May 2009 where four adults
mistook V. oxysepalum for the edible Allium ursinum (wild garlic).22 In the final reported
incident 11 children at a youth camp poisoned themselves by accidentally consuming
small amounts of V. oxysepalum while attempting to prepare herbal tea.23
1.2. V. maackii
V. maackii is native to Asia, commonly encountered in the Henan, Jilin, and
Shandong provinces of China. V. maackii is used in the Chinese traditional medicine
Lilu, which gains its alleged therapeutic benefits from alkaloids, stilbenes, flavonoids,
phenols, and glyceride. V. maackii has been used for thousands of years to treat
symptoms of aphasia caused by jaundice, scabies, apoplexy, and other such ailments. The
plant components are teratogens, which is consistent with other Veratrum alkaloids, and
there are at least nine stilbenes (1. cis-mulberroside A, 2. resveratrol-4,3′-O-β-Ddiglucopyranoside, 3. mulberroside A, 4. gentifolin K, 5. resveratrol-3,5-O-β-ddiglucopyranoside, 6. oxyresveratrol-4′-O-β-d-glucopyranoside, 7. oxyresveratrol-3-O-β-
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d-glucopyranoside, 8. oxyresveratrol, and 9. resveratrol) that have been identified as
bioactive constituents. Stilbenes have anti-oxidant and anti-radical properties that can
lead to prevention of cancer and cardiovascular disease as well as anti-inflammatory and
neuroprotective effects. The anti-oxidant properties of V. maackii stilbenes have been
demonstrated in mice through the reduction of ethanol-associated single-stranded DNA
breaks.26
1.3. V. nigrum
V. nigrum, commonly referred to as black false hellebore, is another plant that
grows in Europe and Asia. This particular species of Veratrum has been used in both
Chinese and Korean medicine. V. nigrum, along with a few other species of Veratrum,
make up the Chinese drug “Yeo-Ro”, which has been used for treatment of headache,
jaundice, chronic malaria, dysentery, scabies, and hypertension.29 In Traditional Korean
Medicine, V. nigrum is fed to patients to induce vomiting as a treatment for dyspnea
caused by a stroke or epilepsy.30 The alkaloids 2, 7, and epi-verazine have been extracted
and used as melanogenesis inhibitors in mice, but the mechanism of action remains
undetermined.29 V. nigrum is used in China to alleviate aphasia in the same way as V.
maackii, and also to treat symptoms of hypertension.30,31 Veratramine has a hypotensive
effect by blocking sodium ion channels and acting as an agonist for serotonin on
presynaptic 5-HT neurons.31
1.4. V. taliense
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Veratrum taliense grows in Europe and Asia, and in the Middle Ages was used in
both places to treat high blood pressure, excess of phlegm, epilepsy, and stroke. The
alkaloids contained within the plant inhibit voltage gated sodium ion channels. Two
examples include 3 and rubijervine, which can block NaV1.5 channels in cardiovascular
muscles and induce cardiotoxicity at elevated levels.33
The roots and rhizomes of V. taliense are a component of the traditional folk
medicine “Pimacao” from the Yunnan province of China. The other constituents of
Pimacao are V. grandiflorum, V. mengtzeanum, and V. stenophyllum. Pimacao is the main
ingredient in “Yunnan Baiyao”, a well-known traditional Chinese medicine for the
treatment of pain caused by fractures, hemorrhage, epilepsy, and rheumatism. The
mechanism of action has not been thoroughly studied because the formula for this
medicine has not been disclosed.16–18,47 Yunnan Baiyao is commonly used for
orthopedics, respiratory care, gastroenterology, and gynecology, but some possible
adverse drug reactions include abdominal pain, chest tightness, nausea, vomiting,
perturbation, and urticaria, among others.47
1.5. V. viride: subspecies V. viride & V. eschscholtzii
V. viride is a species complex of V. viride and V. eschscholtzii.
1.5.1. V. viride
Growing widely across North America, V. viride, also known as green false
hellebore, was used by some Native American tribes to treat a variety of infirmities and
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ailments. For a cold, one would chew on the root; for a snake bite, crushed rhizome was
applied to the wound; and for venereal disease, a tea made from the plant was consumed.
The known ability of V. viride to induce vomiting was also used to determine a worthy
leader in Native American tribes, based on who could resist the emetic properties the
longest. As early as 1835, V. viride was consumed to treat rheumatism and as an antiinflammatory.2 For those with primary hypertension it has also been shown to reduce
high blood pressure by consumption of powdered roots and rhizomes. The alkaloids
germidine and germitrine are responsible for the hypotensive properties. Germidine is a
diester of the known compound germitrine in combination with acetic acid and l-αmetylbutyric acid, whereas germitrine is a triester of the same composition, but with the
addition of d-methylethylglycolic acid. Germitrine, the more effective constituent, was
reported to cause a drop in blood pressure in an anesthetized dog with as little as half a
microgram per kilogram administered intravenously.35
1.5.2. V. eschscholtzii
The second member of the V. viride subspecies complex is Veratrum
eschscholtzii.2 V. eschscholtzii is localized in western North America, stretching from
California to Alaska. The Native American tribes Bella Coola, Cowlitz, Kwakiutl,
Okanagan, Quinault, Salish, Shuswap, and Thompson treated colds and blood, heart,
orthopedic, and skin ailments with this plant as well as using it as a poison, analgesic,
anti-rheumatic, emetic, and laxative.37 For example, it was suggested that a poultice of
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leaves be applied to the body for treatment of pain, or a decoction of the whole plant be
ingested for treatment of rheumatism.38 Isorubijervosine, the glycoside of 3, was first
isolated from this plant along with the already known alkaloids, pseudojervine and 6.39
1.6. V. californicum
V. californicum var. californicum is also referred to as California false hellebore.
It too grows in the western United States but is often found slightly further south. V.
californicum was not traditionally used for medicinal purposes, but instead was noticed
due to its teratogenic effects. During the 1950s in the high mountain meadows of Idaho,
lambs were born with a singular eye in a cyclopean malformation. It was determined that
this was caused by the pregnant ewes consuming V. californicum before giving birth to
offspring. The alkaloids within the plant were determined to be responsible for the
interruption of the hedgehog (Hh) signaling pathway retarding the development of the
embryo, causing improper tissue formation.2
Each of the above listed Veratrum spp. has been studied because each contains at
least one known or suspected alkaloid found within V. californicum. There remain many
gaps in the research of V. californicum as most of the studies were conducted over fifty
years ago; thus, the bioactivity source(s) within each additional Veratrum spp. were
examined in order to provide more information regarding the possible uses of V.
californicum. The alkaloids found in V. californicum have potential to be developed into
cancer therapeutics due to their Hh signaling inhibitory properties.41 In fact, 1 has been
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used as a molecular template to inspire the development of FDA-approved and clinical
trial candidate chemotherapeutics, including glasdegib, saridegib (IPI-926), vismodegib,
and sonidegib.48 Ethanolic extracts of below-ground parts of V. californicum were
examined using high pressure liquid chromatography (HPLC) and mass spectrometry
(MS) analysis, revealing the existence of at least 16 unique components (Table 1.2). Six
of the alkaloids have confirmed identities (green highlight), while five others are
proposed (yellow highlight) and another five are completely unknown (red highlight).42
The remainder of this review will focus on the medicinal relevance, extraction method,
characterization, and bioactivity of each of the eleven known and proposed alkaloids.
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Table 1.2.

Qualitative assessment of Veratrum californicum alkaloids.

Identity *
Cyclopamine (1)
Veratramine (2)
Isorubijervine (3)
Muldamine (4)
Cycloposine (5)
Veratrosine (6)
Verazine (7)
Etioline (8)
Tetrahydrojervine (9)
Dihydrojervine (10)
22-keto-26aminocholesterol (11)
N/A
N/A
N/A
N/A
N/A

[M+H]+ (m/z) Predicted Molecular Formula
412.326
C27H41NO2
410.312
C27H39NO2
414.343
C27H43NO2
458.370
C29H47NO3
574.381
C33H51NO7
572.365
C33H49NO7
398.347
C27H43NO
414.342
C27H43NO2
430.337
C27H43NO3
428.320
C27H41NO3
416.357

C27H45NO2

576.396
574.381
576.397
410.311
412.326

C33H53NO7
C33H51NO7
C33H53NO7
C27H39NO2
C27H41NO2

* Color coding of sections in Table 1.2 correspond to alkaloids that have
been characterized (green), those that have been proposed, but not
confirmed (yellow), and alkaloids that have been detected, but are yet to be
identified (red).

2. Alkaloids Identified in Veratrum californicum
For each V. californicum alkaloid that is known or proposed, the following section
details how these components were characterized based on three criteria: (1) method of
extraction and isolation, (2) process of identification, and (3) reported bioactivity. The
eleven best characterized alkaloids in V. californicum (see Figure 1.1; green and yellow
entries from Table 1.2) were first identified from a variety of different plant species, so a
description of the original discovery has been detailed. In instances where two or more
procedures for extraction from the same species of plant provided the same alkaloid, two
methods have been described: the original and the most up to date refined protocol. They
are presented in the order of alkaloids with a confirmed presence followed by the
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suspected alkaloids. An overview of the methods by which each V. californicum alkaloid
was extracted and its properties and potential medicinal uses are summarized in Tables
1.3 and 1.4.
2.1. Cyclopamine (1)
A modern method of 1 extraction from V. californicum in 2013 included the use
of a Soxhlet apparatus.2 Biomass from root and rhizome was ground to a fine powder and
wetted with 2 mL of 98.3:1.7 Ethanol:Ammonioum Hydroxide (v/v) solution and then
packed into a cellulose extraction thimble. The contents of the thimble were extracted in
a Soxhlet apparatus with two 50 mL portions of 98.3:1.7 EtOH:NH4OH over consecutive
12 h segments. The extract was subjected to rotary evaporation and stored at −20 °C [1].
Beginning with crude alkaloid mixtures, 1 can be separated via HPLC using a C18
column.49,50
Compound 1 can be quantified through LC chromatograms by first generating a
calibration curve from the commercially available standard, then comparing areas under
the curve to experimental values. Once isolated, 1 and its derivatives can be characterized
by MS.49,50 A full list of 700 MHz proton and carbon-13 chemical shift assignments for 1
characterization is available in literature.51
Compound 1 and its derivatives have been shown to inhibit the Hh signaling
pathway. Active during embryonic development, the Hh pathway plays an important role
in limb patterning and specification of cells in the nervous system. Typically dormant in
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cells after embryonic development, aberrant activation of Hh can result in
tumorigenesis.52,53 Compound 1 was the first identified molecule to inhibit the Hh
signaling pathway.54 The activation of the Hh pathway requires signal transduction by the
transmembrane protein smoothened (Smo).55 Compound 1 inhibits the Hh signaling
pathway by blocking smoothened after it binds to an internal helical fold of the
transmembrane portion of the receptor protein.56 In most adult tissues, the Hh signaling
pathway is inactivated.57 Aberrant Hh activation can lead to oncogenesis, but 1 and its
derivatives are promising therapeutic agents that can be used for treatment. Two such
derivatives are KAAD-cyclopamine and saridegib. 58,59 Both have higher potency and
stability compared to 1. In addition to targeting Smo and blocking Hh signaling, 1 can
also interfere with myriad other harmfully mutated biological processes: it has been
shown to inhibit growth of breast cancer and erythroleukemia cells through mechanisms
outside of Smo binding 60,61, and has been shown to induce apoptosis in human prostate
cancer cells.62 Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is
an extremely useful cancer treatment that kills only cancerous cells without disturbing
normal cells. Cancer cells located in the stomach are resistant to TRAIL due to an
absence of death receptor 5. Compound 1 causes increased expression of death receptor 5
in TRAIL-resistant gastric cancer cells, making them more susceptible to TRAIL.63
Outside of cancer cell suppression, 1 blocks transcription of human respiratory syncytial
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virus both in vitro and in vivo and also holds some promise in future treatment of
psoriasis by promoting healing of psoriatic skin lesions.64,65

Veratramine (2)

Cyclopamine (1)

Sample Preparation *

Separation
Technique
HPLC

Reference
s
LC-MS, 1H and 13C NMR [2,51]

Identification

1
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[49,50]
Flash chromatography H and C NMR, HPLC- [66]
with silica gel
MS, crystallization,
melting point, and HPLCCAD.
V. viride
Benzene, ammonia, acetic High-speed counter- HPLC, MS and NMR
[67]
acid, and NaOH
current
extractions
chromatography
V. oxysepalum Diethyl ether and
N/A
HPLC-MS
[68]
dichloromethane
extractions
V. nigrum L.
Ethanol and then
Column
Crystallization
[69]
chloroform extraction
chromatography
V. grandiflorum Crystallization and
N/A
Crystallization, melting
[70]
filtration using 2 Npoint, and NMR
calcium acetate and acetic
acid (Unk plant part)
V. californicum Dried and ground, ethanol HPLC
HPLC, CAD and MS
[71]
then chloroform extraction

V. californicum Soxhlet extraction with
ethanol/ammonium
hydroxide
Ethanol soak
V. viride
Ethanol and chloroform
extraction

Plant(s)

Methods of extraction, separation, and identification of Veratrum alkaloids.

Alkaloid

Table 1.3.
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V. patulum

Veratrosine (6)

Verazine (7)

V. californicum

Cycloposine (5)

Zygadenus
sibiricus

V. californicum

V. californicum

V. viride Aiton

Craig countercurrent N/A
distribution
Silica gel column
NMR and ESI-MS.
chromatography and
MPLC
Ethanol and chloroform Flash
IR, LC-MS, 1H and 13C
extraction (Unk plant
chromatography with NMR
part)
silica gel
Benzene and 5% NH4OH Column
HPLC-ELSD, MS m/z =
soak (Unk plant part)
chromatography with 458.37
silica
gel/benzene/methanol
slurry
Dried and ground, ethanolHPLC-ELSD
HPLC-MS spectra
then chloroform
confirmation
extraction
Ethanol soak, chloroform Silica gel,
HPLC-MS m/z and
extraction, alkaloid
recrystallization in elution times
residue
acetone
Dried and ground, ethanolHPLC-ELSD
then chloroform
extraction
N/A (From aerial plant) N/A
N/A

V. eschscholtzii Chloroform extraction
Gray
(Unknown plant part)
V. taliense
Methanol extraction

Muldamine (4)

Isorubijervine (3)

[75]

[71,73,74]

[71,73,74]

[73]

[66]

[33]

[72]
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Tetrahydrojervine (9)
Dihydrojervine (10)
22-Keto-26-amino
cholesterol (11)

Etioline (8)

Solanaceae
Dried, ground and refluxed Vacuum liquid
N/A
Solanum
with CHCl3
chromatography and
hypomalacophyll
column
um
chromatography
Asteraceae
EtOAc and MeOH
Silica gel columns and MeOH crystallization and
Eclipta alba
extraction from leaves
preparative TLC
DEPT, HETCOR, HMQC,
and HMBC NMR
V. nigrum
Ethanol extraction
Alkali-treated silica Specific TLC fractions
followed by two CHCl3
gel and TLC
were recrystallized
extractions (Unknown
plant part)
V. nigrum
Three methanol extractions Silica gel column
Recrystallization, ESI-MS,
chromatography twice IR, 1H and 13C NMR
and HPLC
13
Solanum spirale Dried and ground, Soxhlet Silica gel
C NMR and atom probe
extraction with ethanol,
chromatography
chloroform/methanol
extraction
Lilium candidum Ethanol extraction from TLC with chloroform TLC with chloroform and
L.
bulbs and then CHCl3
and methanol
methanol
extraction
N/A
Synthesized only
N/A
Synthesized only
N/A
Cholesterol metabolite,
proposed

[81,82]

[80]

[79]

[29]

[78]

[77]

[76]
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2.2. Veratramine (2)
Compound 2 has been extracted from many different Veratrum spp., including V.
viride 66,67, V. oxysepalum 68, V. nigrum L. 69 and V. grandiflorum 70. One method of
extraction from V. viride involved percolation with 95% ethanol, followed by
evaporation, resuspension in 5% tartaric acid, and filtration. Additional percolation of the
filtrate was performed with chloroform, where the extract was subjected to pH
adjustment and solvent evaporation. Flash chromatography with silica gel was used to
separate 2 from other alkaloids.66 Another method of extraction from V. viride involved
grinding the roots and rhizomes to a powder, and then performing extractions using
benzene and dilute ammonia. Additional extractions were performed with acetic acid,
NaOH, and again with benzene until a crude alkaloid mixture was produced. In order to
purify 2 from the mixture, ammonium sulfate was added and the resulting mother liquor
was diluted with ammonia until the alkaloid could be removed with 50% ethanol.67 An
alkaline solution of powdered V. oxysepalum biomass was refluxed with ethanol and
filtered. Additional extractions of the filtrate with diethyl ether and dichloromethane were
performed, resulting in a crude extract of alkaloids. The isolation of 2 from V.
oxysepalum was carried out via a two-step use of high-speed counter-current
chromatography (HSCCC).68 In order to remove the alkaloids from V. nigrum L.,
extractions were first performed with 95% ethanol. After concentration, the pH was
lowered to 3 using hydrochloric acid, and then the solution was filtered. The pH of the
filtrate was raised to 10 using ammonium hydroxide, and additional extractions of crude
alkaloids were performed with chloroform. Separation of alkaloids was achieved via
column chromatography.69 The resinous material of V. grandiflorum passed through a
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series of crystallizations and filtrations over a period of several days. The mother liquor
from the crystallization of jervine hydrochloride was dissolved in 0.5 N-acetic acid, and 2
N-sodium sulfate was added, eventually leading to formation of veratramine sulfate and
then 2.70
After extraction from the roots and rhizomes of V. viride, 2 was characterized in
different solvents using 1H and 13C NMR.83 After 2 was separated from a crude extract of
V. oxysepalum, the data from HPLC, MS, and NMR were analyzed to confirm its
identity.68 A C18 column was used for HPLC-MS isolation of 2 from V. nigrum L. This
was followed by ESI-MS analysis in a m/z range of 200–700 amu.84 The alkaloid quantity
from V. californicum was determined using HPLC with a charged aerosol detector (CAD)
and MS via calibration curves that were determined in triplicate in accordance with a
purchased standard (2). Identification of the alkaloid was performed with HPLC-MS.71
Melting point has been used for characterization, as colorless needles of 2 melt at 209.5
to 210.5 °C. The specific rotation values were found to correspond closely to calculated
values. The mother liquor of a crude jervine hydrochloride from V. viride had excess
ammonia added until separation of 2 was achieved. The product was recrystallized and
jervine contaminants were removed to achieve the same melting point as above. In order
to confirm that 2 had indeed been produced, the product was acetylated and compared to
triacetylveratramine, and was found to possess the same properties and melting point.
Specific rotation values were also calculated and verified with experimental results.67
Compound 2 has been tested for inhibition of prostate cancer by interfering with
the Hh signaling pathway, and in conjunction with other alkaloids, has been used for
treating high blood pressure, apoplexy, and other ailments.83,84 Bioactivity of 2 was
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measured in various ways. The ability of 2 to inhibit the growth of cancerous cells on a
malignant PC-3 cell line was tested, and a wound-healing assay was also performed. Out
of nine alkaloids tested in the wound-healing assay, 2 and its derivatives exhibited the
highest degree of anti-migratory activity, and at a concentration of 50 µM, 2 displayed
the highest degree of prevention of proliferation of cancerous cells.83 In another study, 2
was introduced to two different groups of rats by gavage at doses of 0.25 or 2.50 µmol/kg
for seven days to test its neurotoxicity both in vivo and in vitro using rat liver
microsomes. DNA was damaged in the cerebellum and the cerebral cortex at both high
and low doses of 2 as detected using the alkaline comet assay.84
2.3. Isorubijervine (3)
Compound 3 has been found in many different species of Veratrum. Isolation of 3
from V. eschscholtzii Gray was achieved by crude chloroform extraction. A Craig
countercurrent distribution was performed on this extract to separate the alkaloids and
identify 3.72 In a separate study, the roots and rhizomes of V. taliense were dried and
ground before being extracted with methanol. After solvent acidification, the extract was
filtered, and then base was added before silica gel column chromatography (CC) was
utilized for component separation. The second eluted fraction underwent medium
pressure liquid chromatography (MPLC) to yield 3.33 This alkaloid was also obtained
from V. viride Aiton through a series of ethanol and chloroform extractions. The
identification of specific alkaloids was made possible after flash chromatography was
performed using silica gel.66
The amount of 3 contained in the extract from V. californicum was quantified by
creating a calibration curve for HPLC using commercially available 3. In order to
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determine measurement of 3, the HPLC was attached to a CAD and an MSQ plus MS.71
Compound 3 was identified from the extract of V. taliense using NMR and ESI-MS.33
The melting point of the colorless needles of isorubijervine was found to be 241–242 °C.
IR, LC-MS, and 1H and 13C NMR were used to characterize this compound.66
The traditional medicinal benefits of this alkaloid include the treatment of pain
and hypertension, but the mechanism remains unknown.31,33 Compound 3 has been used
to treat high blood pressure and pain, but has also been found to cause toxicity to the
heart. The LD50 of 3 was found to be 1.14 mg/kg in mice. Administration of 3 to rats and
macaques resulted in bradycardia and hypotension that lasted for several minutes; the
response observed in macaques was dose-dependent. Nav1.5 sodium channels expressed
in HEK293t cells, which are critical to cardiovascular function, were treated with 3. The
IC50 value was found to be 6.962 ± 0.422 µM, and a 5 µM dose led to a 41% decrease in
current. This decrease in flow in the sodium channel may explain the symptoms of
bradycardia in the animals.33
2.4. Muldamine (4)
Compound 4 was extracted by soaking V. californicum in a benzene/5% NH4OH
(3:1 v/v) solution for 24–48 h. This solution was then dried in vacuo to produce a mixture
of alkaloids that were recrystallized first in an acetone/water solution and then in a
methanol/water solution. The recrystallized alkaloid mixture (300 mg) was dissolved in
benzene/methanol (10:1, 3 mL) and loaded onto a chromatography column packed with a
slurry of silica gel and benzene/methanol (60:1). Elution was performed using a
benzene/methanol solution (60:1, 20:1). Isolation of 4 was performed using HPLC-ELSD
in combination with manual fraction collection of individual peaks.73
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Compound 4 has been characterized by a m/z of 458.37.73 The identity of 4 was
verified using a commercially available standard.
Initially given the name alkaloid Q, 4 is produced by V. californicum and is
known to be a Hh signaling pathway antagonist as well as a non-depolarizing action
potential blocker in the giant axon of squid and crayfish.2,74,81 Compound 4 is not
teratogenic in sheep, but did demonstrate marginal activity as a teratogen in hamsters.82
The bioactivity of 4 was tested in combination with 2 and 3 by measuring Gli protein
activity in Shh-Light II cells.74 The Gli family members are transcription factors that can
be monitored in order to determine whether the Hh pathway is activated or not.85,86 The
results demonstrated that the combination of alkaloids did have an inhibitory effect on Hh
signaling.74
2.5. Cycloposine (5)
In a 2019 study by Turner et al., 5 was obtained by first cutting the rhizome/root
of V. californicum into 1–2 cm cubes and lyophilizing it to dryness over 24–48 h. The
dried biomass was then submerged in liquid nitrogen and ground to a fine powder using a
mortar and pestle. Powdered biomass (2.0 g) was added to 95% ethanol (100 mL) and
sonicated for 30 min, then mixed on a stir plate for 24 hrs. Plant material was removed
via vacuum filtration and discarded. Ethanol was separated from the resulting solution by
rotary evaporation, yielding brown oil. The crude alkaloid product was dissolved in 95%
ethanol (10 mL), warmed to 40 °C, and sonicated to ensure all alkaloid product was
dissolved. An aqueous ammonia solution (35% v/v) was added to obtain an alkaline
solution (pH ≥ 10). This solution was eluted through a supported liquid extraction column
with chloroform (3 × 10 mL) using a vacuum manifold (2 mbar). The fractions were
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combined, filtered and dried. The dried alkaloids were then dissolved in 100% ethanol.71
HPLC-ELSD was used to separate individual alkaloids from the mixture.73
Compound 5 was identified by HPLC-MS by comparison to a commercially
available standard.71,74
Compound 5 is a teratogenic alkaloid produced exclusively in V. californicum.2
This alkaloid is relevant to medicine through its use in the development of modern cancer
treatments.2 Shh-Light II cell models demonstrated that 5 did not contribute to Hh
signaling inhibition in this method of bioactivity analysis; however, deglycosylation from
hydrolysis during digestion may contribute to teratogenicity.74
2.6. Veratrosine (6)
In 1998, researchers conducted an extraction of V. patulum by cutting the roots
into small pieces and soaking them in ethanol (4 × 7 L). The four ethanol solutions were
concentrated in vacuo to form a residue that was dissolved in 5% aqueous tartaric acid
solution (2.5 L); insoluble materials were removed by filtration. The solution was
defatted with ether (4 × 3 L) and made alkaline with 20% Na2CO3 to pH 10. Extraction
was performed with CHCl3 (4 × 500 mL), where all chloroform extractions were
combined and dried to form an alkaloid residue.87 The alkaloid components in the V.
patulum extract were separated by column chromatography using alkali-treated silica gel
(400 g) and a mobile phase of MeOH-CHCl3 (2:98, 6:94, 10:90, and 15:85). Thin layer
chromatography (TLC) was used to monitor eluates with a total of 26 fractions collected.
Fraction 23 was recrystallized with acetone to yield 6 (mp 242–244 °C).87
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In 2013, 6 was identified from a V. californicum ethanol extract using HPLCELSD.73 Most recently, the identification of 6 has been accomplished using HPLC-MS
and verified by comparing the elution time of a commercially available standard.71,74
When ingested, 6 is an antagonist of epinephrine and norepinephrine.88 In ShhLight II cell models it was shown that 6 did not contribute to Hh signaling inhibition;
however, hydrolysis of the glycosidic linkage during digestion may contribute to
teratogenic effects.74
2.7. Verazine (7)
Compound 7 has been extracted from different plant families including Lilaceae
in both species Veratrum (nigrum) and Zygadenus (sibiricus), Solanaceae Solanum
(hypomalacophyllum), and Eclipta (alba).29,76–78 The roots of Solanum
hypomalacophyllum were dried and ground to a powder before 10% NH4OH was added.
The basic mixture was refluxed with CHCl3 and dried. Fractions were collected after
using vacuum liquid chromatography and various forms of column chromatography with
CHCl3-MeOH and H2O-MeOH gradients, resulting in both epimers of 7 (20S and 20R).76
Dried leaves from Asteraceae Eclipta alba were extracted using both EtOAc and MeOH.
A silica gel column was used with Me2CO in CHCl3 to elute fractions, which were
purified using a second silica gel column and preparative TLC. Compound 7 was also
crystallized from MeOH.77 Extraction from the roots and rhizomes of V. nigrum L. var.
ussuriense was done using ethanol after the plant matter had been dried and portioned
into small pieces. The extract was concentrated in vacuo before the addition of a 5%
aqueous tartaric acid solution. After the sample was filtered, ether was added, and then
another extraction was performed using CHCl3. A 20% aqueous Na2CO3 solution was
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added to the aqueous portion until a pH of 6 was achieved. Another CHCl3 extraction was
performed, and the product was dried before separation by chromatography using alkalitreated silica gel with different concentrations of mobile phase MeOH-CHCl3. TLC
separated the fractions, and fractions 5–7 were combined and recrystallized from acetone
yielding 7.78 Another extraction from the crushed roots of V. nigrum was performed using
methanol, repeated three times. The extract was diluted with water before being separated
into different layers using n-hexane, chloroform, and butanol. The butanol layer
underwent silica gel column chromatography twice, first using acetonitrile-methanol, and
then using n-hexane-acetone-methanol. Finally, three different compounds were isolated
using HPLC.29
Compound 7 is usually in the form of colorless needles, and the melting point is
between 175 and 177 °C. High resolution ESI-MS was used in order to identify the
molecular weight as 397.65 amu and the molecular formula as C27H43NO.29 Compound 7
is typically characterized via NMR and sometimes IR. The spectra are well established,
so the presence of 7 can be confirmed by spectral comparison.89 Important IR, 13C and 1H
NMR chemical shifts are those of the alcohol, imine, specific methyl groups, and singular
hydrogen and carbon atoms, which have all been described.29 Assignments of chemical
shifts have also been obtained using a variety of NMR experiments including DEPT,
HETCOR, HMQC, and HMBC.77 Deuterochloroform was used as the solvent for the 1D
1

H and 13C and 2D double quantum filter COSY and NOESY NMR spectra of 7.90
The medicinal properties of 7 have been examined for use as an antifungal agent

or a potential melanogenesis inhibitor, but the mechanism of action is still being
explored.29,77,82,91 Most 7 bioactivity appears to be antifungal. In one study, steroidal
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alkaloids were used as inhibitors of Candida albicans and Trichophyton spp.; 7 was a
successful inhibitor with a minimum inhibitory concentration of 6.2 µg/mL for C.
albicans and 3.1 µg/mL for T. rubrum.91 Yeast assays using the Sc7 yeast strain were
inhibited by 7, but when examining cytotoxicity, the results were not as favorable; IC50
values were greater than 10 µg/mL. Due to this cytotoxicity, antifungal studies were
aborted.77 Compound 7 was also studied for potential use as a melanogenesis inhibitor.
The IC50 was less than 1 µg/mL for inhibiting melanin biosynthesis in B16 FI mouse
melanoma cells.29
2.8. Etioline (8)
Compound 8 was extracted from the root of Solanum spirale. The roots were
heated, dried, and ground to a powder prior to undergoing a Soxhlet extraction with
ethanol. The ethanol was evaporated under vacuum and partitioned evenly between 10%
C6H6-Et2O and HOAc. Ammonia was added, and a second extraction was performed with
CHCl3-EtOH. The solvents were again evaporated, and silica gel was used to obtain an
elution of 8 with CHCl3-MeOH.79 Compound 8 has also been extracted from Lilium
candidum L. bulbs using ethanol. This extract was combined with HCl for three days
before the pH was raised using ammonia, and the resulting aqueous portions were
extracted with CHCl3.80
To characterize the Solanum spirale extracted alkaloids, analysis by NMR
spectroscopy was pursued. The 13C NMR spectrum of the alkaloid suspected to be 8 was
compared to solafloridine, 20-isosolafloridine and 20,25-bisisoetioline, and supported by
atom probe chromatography measurements.79 The Lilium candidum L. extract was
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examined via TLC with CHCl3:MeOH, resulting in the identification of jatropham and
22,26-epiminocholestane-type steroidal alkaloid, which is consistent with 8.80
Compound 8 has been tested for the treatment of Hepatitis B, and has proven to
be effective in specific contexts.92 PLC/PRF/5 cells were prepared from human
hepatoma, which were constantly excreting hepatitis B surface antigen, while KB cells
were of the HeLa cell line and believed to possess human papillomavirus-18 (HPV18).92,93 Compound 8 was applied to these human PLC/PRF/5 and KB cells in vitro, and
it was found that it only significantly inhibited the human PLC/PRF/5 cells, showing
inhibition of Hepatitis B virus, but not of HPV-18.92
2.9. Tetrahydrojervine (9)
Compound 9 results from the reduction of the C5-C6 and C12-C13 double bonds
in jervine and has been hypothesized to occur in V. californicum due to the presence of
jervine.41,94 In past experiments, 9 was artificially synthesized through the reduction of
jervine using PtO2 in acetic acid.95
A physical property that assists identification of 9 is its melting point of 221 °C
(decomposition).95 Characterization of 9 has involved specific rotation measurements and
use of the Zerewitinoff determination to identify active hydrogen atoms for the purpose
of aiding structure determination.96,97 Possible methods of characterizing this alkaloid
such as NMR, HPLC, and GC-MS have not been reported in the literature.
Compound 9 has not been used as a medicine, but has been used as a tool to
examine the effects of Veratrum alkaloids on embryonic development.41 Studies
involving 9 investigated the relative teratogenic potency of jervines and how saturation of
the C5-C6 bond led to less severe Hh pathway inhibition.95 Compound 9 was tested on
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explants of the intermediate neural plate region of Stage 9–10 chick embryos. Explants
were treated with 9 in 48 nM and 240 nM concentrations and tested for induction markers
of floor plate (HNF-3β) and motor neuron (Isl1/2) differentiation with the goal of
inhibiting their growth. Compound 9 produced only 43% inhibition of HNF-3β at 240
nM.98 In another study, it was determined that 9 was significantly less teratogenic than
jervine, 10, and 1. Pregnant Syrian hamsters that were dosed with jervine produced
fetuses where 92% possessed malformations, whereas only 14% of fetuses had
malformations when exposed to 9 during gestation.95
2.10. Dihydrojervine (10)
Compound 10 is synthetically obtained by reducing the C12-C13 double bond of
jervine using PtO2 or LiAlH4. The latter yielded a mixture of oils and crystalline products
which included 10 as the major one.99
The successful formation of 10 is confirmed by 13C NMR through loss of the
double bond signals at 137.2 ppm and 146.4 ppm and a shift of the methyl carbon C21 of
jervine found at 12.4 ppm to 10.5 ppm in the spectrum.100
Compound 10 was tested on the human metastatic prostate cancer PC-3 cell line
with wound-healing assays to monitor migration and with 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl tetrazolium bromide (MTT) to test proliferation. At a 50 µM concentration,
10 did inhibit cancer growth, but it was ineffective in the wound-healing assay.83
2.11. 22-Keto-26-aminocholesterol (11)
Compound 11 has not yet been definitively identified from V. californicum, but is
suspected based on mass spectrum data and a compound library screen.81,82 Compound
11 is not typically a stable compound and thus will undergo ring-closing to yield 7; it has
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not been isolated previously. 22-Hydroxy-26-aminocholesterol can be oxidized by 22hydroxy-26-aminocholesterol 22-oxidase to form 11.81,82 It is a potential intermediate in
the biosynthesis of 7 and 1.82
A summary of bioactive V. californicum alkaloids can be found in Table 1.4.
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Table 1.4.
Alkaloid

Summary of bioactivity in Veratrum californicum alkaloids.

Method of Testing
Efficacy
Inhibition of growth of estrogen Significant effects at both
Cyclopamine (1)
receptor positive cell line MCF7
10 and 20 µM
Inhibition of proliferation of
Strong effect at 40 µM
HEL and TF1a cells
Induced apoptosis in human
40 µM
erythroleukemia cells
Significant inhibition at
Inhibition of growth of LNCaP
100 nmol/L and IC50 of 11
C4-2B cells
µmol/L
<75% viability at 20 µM
Decreased cell viability
with 50 ng/mL TRAIL in
TRAIL-resistant AGS cells
Inhibition of hRSV infection in
IC50 of 36 nM
vitro
Reduction by 1.5 logs at
Reduction of lung hRSV titers
100 mg/kg
Inhibition of progression of
<40% proliferation at 50
Veratramine (2)
human prostate metastatic
µM dose
cancer cell line PC-3
Inhibition of progression of
<20% migration at 50 µM
human prostate metastatic
dose
cancer cell line PC-3
In both cerebellum and
Number of DNA-strand breaks cerebral cortex: >0.5 µm
in the cerebellum and cerebral
tail moment with 0.25
cortex of mice
µmol/kg dose, >1.0 µm tail
moment with 2.5 µmol/kg
Isorubijervine
Inhibition of rNaV1.3
IC50 of 12.14 ± 0.77 µM
(3)
Inhibition of rNaV1.4
IC50 of 9.82 ± 0.84 µM
Inhibition of rNaV1.5
IC50 of 6.962 ± 0.422 µM
5 µM dose led to 41%
Inhibition of rNaV1.5
decrease in current
Lethal dose in mice
LD50 of 1.14 mg/kg
Blocks action potential in squid Little or no depolarization
Muldamine (4)
and crayfish giant axons
at 1 × 10−4 M
Minimum inhibitory
Verazine (7)
Antifungal
concentration of 6.2 µg/mL
for C. albicans
Minimum inhibitory
Antifungal
concentration of 3.1 µg/mL
for T. rubrum

Reference
[60]
[61]
[61]
[62]
[63]
[101]
[101]
[83]
[83]

[84]

[33]
[33]
[33]
[33]
[33]
[102]
[91]
[91]
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Inhibition of melanogenesis in
B16 FI mouse melanoma cells
Inhibition of hepatitis B in
Etioline (8)
PLC/PRF/5 cells
Inhibition of progression of
Dihydrojervine
human prostate metastatic
(10)
cancer cell line PC-3

IC50 < 1 µg/mL

[29]

EC50 of 2.67 µg/mL

[92]

<40% proliferation at 50
µM dose

[83]

3. Conclusions
V. californicum contains a multitude of bioactive alkaloids with potential to be
developed into therapeutic drugs. Compound 1 is an alkaloid from V. californicum that
has inspired novel Hh pathway inhibiting cancer treatments. There remain many alkaloids
in V. californicum that have yet to be fully characterized. Advances in separation and
identification methods, materials, and instrumentation sensitivity have permitted
detection of alkaloids beyond those that have been characterized prior. An assessment of
the strategies for extraction, isolation, and characterization of known alkaloids has been
presented in an effort to extend existing knowledge of these compounds to alkaloids that
have been detected, but not yet characterized (Figure 1.1, Table 1.2). Utilization of the
methods summarized in Table 1.3 may permit the identification of additional alkaloids
beyond those that are known, so that the identity of all 16 detected components can be
accomplished and sufficient quantities of purified alkaloids can be assessed for
mechanisms of activity. Veratrum plants are a well-known source of medicinal
components and the discovery of new compounds in Veratrum californicum with
favorable therapeutic properties serves as a compelling pursuit.
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CHAPTER TWO: EXTRACTION AND SEPARATION OF VERATRUM
CALIFORNICUM ALKALOIDS
Introduction
In the 1950’s in the high mountain meadows of central and southern Idaho,
sheepherders found that 1%-25% of their lambs were born with a craniofacial
mutation.86,103 These “monkey-faced” sheep had malformations affecting their eyes, jaws,
skulls, and sometimes brains, with the most obvious mutation being a single, large,
cyclopean eye located centrally on their face.103 The Poisonous Plant Research
Laboratory (PPRL) in Logan, Utah was tasked to determine the cause of these
deformities in 1954.86 It was originally believed the cause of the deformities was due to a
recessive genetic trait, but in 1957 a breeding experiment provided evidence that negated
this theory.103 Field and feeding studies were conducted on the sheep population to
identify causative agents.
Veratrum californicum wasn’t considered a possible source of developmental
deformities in the lambs’ until 1958 when a sheepherder mentioned it can cause illness in
the sheep when they consume it. Soon PPRL scientists initiated feeding trials where their
results showed the sheep had a range of symptoms including excessive salivation and
frothing at the mouth, vomiting, walking unusually, irregular heartbeat, vomiting,
dyspnea, convulsions, coma, and death. In 1959 the first lamb with a cyclopic
malformation was born during a feeding trial, and six years later enough studies had been
conducted to definitively correlate deformities in lambs to the day of gestation the
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pregnant ewes grazed on V. californicum. It was determined that a ewe consuming the
plant on day 14 of gestation gave birth to a lamb having a proboscis-like nose above a
cyclopic eye.2,86
In 1968 the steroidal alkaloid cyclopamine was isolated from the extract of V.
californicum, and by 1969 the structure was published.104,105 Upon analysis of the
scientific literature, it was discovered that cyclopamine had originally been isolated from
Veratrum grandiflorum and had been named 11-deoxojervine by a Japanese research
group in 1965.86 Cyclopamine in combination with cycloposine and jervine were
determined to cause cyclopia in lambs. This was the first time that Veratrum alkaloids
had been considered teratogenic, whereas previously cevanine-type alkaloids had been
focused on due to their hypotensive properties.2
The extraction and isolation of alkaloids from V. californicum continued into the
1970’s, followed by several decades of inactivity in the research outside of cyclopamine
bioactivity exploration. By 2008, access to modern instrumentation with more sensitive
detectors, and analytical techniques like solid phase extraction with increased analyte
recovery have greatly improved the extraction, separation, isolation, characterization, and
bioactivity assessment of steroidal alkaloids like those prevalent in V. californicum
extract. In our lab we have been able to detect and identify less abundant alkaloids that
were not previously detected from V. californicum.73 Evaluation of eight literature
protocols for the extraction of cyclopamine from V. californicum, dating back to the
1950’s, led to determination that ethanol soak yielded the greatest magnitude of total
alkaloids with the highest level of bioactivity.49 An investigation was performed
quantitatively to establish the composition of cyclopamine, veratramine, muldamine, and
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isorubijervine contained within the leaf, stem, and root/rhizome of the plant.74 This study
was developed further by uncovering quantitative variation in the amount of the four
previously listed alkaloids by plant part, harvest location, and growth stage. During this
process at least six new, uncharacterized alkaloids were discovered.71 These
uncharacterized alkaloids exhibited Hedgehog pathway suppression activity, which
inspired the current work. First, Turner’s ethanol extraction method of 2 g plant material
in 100 mL of 95% ethanol was attempted, but the resulting HPLC chromatograms had
very little detection. 71 The concentration of starting material was modified until the
chromatograms permitted correlation of retention times and predicted alkaloid
identification (25 g plant material in 50.0 mL of 95%). A separation method consisting of
a 30 min run duration was divided into five segments by time. Collection began for
fraction 1 starting at 10.75 min and ending at 13.25 min. Fraction 2 was started
immediately after for another collection period of 2.5 min, and this pattern continued
until all five fractions were gathered. Each fraction contained between three and ten
peaks of interest. Chromatographic analysis and mass spectrometry were used to identify
the alkaloids.
Interest in the V. californicum alkaloids originates from their activity to inhibit the
Sonic hedgehog (Shh) signaling pathway.106 This pathway is responsible for proper cell
polarization, limb formation, central nervous system development, and most epithelial
tissue differentiation in animals leading to bilateral symmetry.71,107–110 Over twenty
cancers correlate to aberrant Hedgehog signaling (Hh) for propagation. When the Hh
pathway is blocked during normal embryonic development, the consequences are severe,
but this same mechanism of action can be used to treat cancer.2,71
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Results
Raw extract was collected from the root and rhizome of V. californicum and was
compared to the literature extract reported by Turner et al., using high performance liquid
chromatography (HPLC) with a diode array detector (DAD) as seen in Figure 2.1 a-c.
Buffer A was 0.1% Trifluoroacetic acid in water, and Buffer B was HPLC grade
acetonitrile. A linear gradient was used starting at 15% Buffer B and increasing to 60%
Buffer B over a period of 25 min. From 25.1 to 30.0 min Buffer B was set to 15%. A
semi-preparatory Agilent Zorbax SB-C18 column (9.4 x 250 mm, 5 µm) was used with a
flow rate of 3.0 mL/min. Five fractions were collected by time using this same method,
with the collection periods described below. Figure 2.1 a. shows Turner’s literature
extract, Figure 2.1 b. shows the raw alkaloid extract for the current work, and Figure 2.1
c. shows the two overlaid.
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Figure 2.1
Chromatograms of Veratrum californicum raw extract using HPLCDAD. A. most recent chromatogram of literature extract, B. extract chromatogram
from current work, and C. overlay of the two extracts, where the literature extract
is in red and the current work is shown in black
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The extract was also analyzed using a charged aerosol detector (CAD) as in
Figure 2.2 a. The solvents and gradient were the same for this method as the one
described above, but the flow rate was lowered to 0.3 mL/min for a Thermo Acclaim 120
C18 column (2.1 x 150 mm, 3 µm). The chromatograms of the fractions as captured by the
CAD can be seen in Figure 2.2 b-f., where Figure 2.2 b. shows fraction 1 (collection
time 10.75 to 13.25 min), Figure 2.2 c. shows fraction 2 (collection time 13.25 to 15.75
min), Figure 2.2 d. shows fraction 3 (collection time 15.75 to 18.25 min), Figure 2.2 e.
shows fraction 4 (collection time 18.25 to 20.75 min), Figure 2.2 f. shows fraction 5
(collection time 20.75 to 23.25 min), and Figure 2.2 g shows as an overlaid view of each
fraction.

42

Figure 2.2

Chromatograms of Veratrum californicum raw extract and five
fractions using HPLC-CAD

Each fraction as well as the raw extract was analyzed by high resolution mass
spectrometry (MS) in order to determine molecular weight (m/z) and predicted molecular
formula for alkaloid identification. An XTerra MS C18 column, 3.5 μm, 2.1 x 150 mm
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(Waters, Milford, MA, USA) was utilized with a flow rate of 200 µL/min. The solvent
system was 5% acetonitrile and 0.1% formic acid in water (Buffer A) and acetonitrile and
0.1% formic acid (Buffer B). A linear gradient was used starting at 5% Buffer B and
increasing to 70% Buffer B over a period of 25 min. The mass spectra and extracted ion
chromatograms of prominent peaks corresponding to abundant alkaloids in each of the
five fractions collected from the extract are shown in Figures 2.3-2.7.
The LC-MS examination of fraction 1 revealed the presence of four alkaloids
peaks, which can be seen with their corresponding extracted ion chromatograms in
Figure 2.3.

44

Figure 2.3
Chromatogram and extracted ion chromatogram for each alkaloid
present in fraction 1, which corresponds to Rt from 10.75 – 13.25 min of crude
extract chromatogram.
Fraction 1 contains four alkaloids as shown in Figure 2.3 a. The peaks appeared
to be paired with 1 and 3 sharing nearly identical m/z ratios of 572.3284 and 572.3271
(Figure 2.3 b. and d.) and peaks 2 and 4 following the same pattern with m/z ratios of
574.3451 and 574.3428 (Figure 2.3 c. and e.) respectively. The predicted chemical
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formulas are C33H49NO7 for peaks 1 and 3 and C33H51NO7 for the peaks 2 and 4. The
reasonable identity of these alkaloids is veratrosine, cycloposine, and isomers of each.71
Fraction 2 had more alkaloid peaks than any other fraction. The mass
spectrometry data aligned with the HPLC chromatogram for these ten compounds can be
found in Figure 2.4.

Figure 2.4
Chromatogram and extracted ion chromatogram for each alkaloid
present in fraction 2, which corresponds to Rt from 13.25 – 15.75 min of crude
extract chromatogram.
Fraction 2 demonstrates at least 10 distinct peaks as shown within the
chromatogram found in Figure 2.4 a. There is some overlap in peak retention times
between fractions 1 and 2. Figure 2.4 b. shows peak 1 with an m/z of 574.3425 and an
elution time of 15.7 minutes, which corresponds to peak 2 of fraction 1 (Figure 2.3 c.).
Peak 2 in Figure 2.4 c. has an m/z of 572.3264 and elution time of 16.0 min, which is the
same as peak 3 from fraction 1 (Figure 2.3 d.), which was predicted to be an isomer of
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veratrosine. Peak 3 from fraction 2 (Figure 2.4 d.) with an m/z of 576.3573, an elution
time of 16.1 min, and a predicted molecular formula of C33H49NO7 (identity unknown)
does not have a peak corresponding to fraction 1. Neither does peak 4 (Figure 2.4 e.)
with an m/z of 430.3073, elution time 16.2 min, and predicted molecular formula of
C27H43NO3. This molecular formula is consistent with tetrahydrojervine.71 Figure 2.4 f.
contains peak 5 with an m/z of 574.3424 and an elution time of 16.5 min, which matches
that of peak 4 from fraction 1 (Figure 2.3 e.). Thus, this peak is also predicted to be an
isomer of cycloposine. Peak 6 (Figure 2.4 g.) had an m/z of 618.3671, an elution time of
16.6 min, and a predicted molecular formula of C35H55NO8 (identity unknown). Figure
2.4 h. shows peak 7 with an m/z of 578.3745, elution time of 16.9 min, and predicted
molecular formula of C33H55NO7 (identity unknown). Figure 2.4 i. displays peak 8,
which had an m/z of 472.3148, elution time of 17.2 min, and predicted molecular formula
of C29H45NO4 (identity unknown). Peak 9 (Figure 2.4 j.) had an m/z of 620.3871, an
elution time of 17.3 min, and a predicted molecular formula of C35H57NO8 (identity
unknown). Finally, peak 10 (Figure 2.4 k.) had an m/z of 410.2828, an elution time of
17.6 min, and a predicted molecular formula of C27H39NO2, which was confirmed to be
veratramine.
Fraction 3 had the fewest number of alkaloids of any fraction. The mass spectra
for each of the three peaks identified on the HPLC can be seen in Figure 2.5.
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Figure 2.5
Chromatogram and extracted ion chromatogram for each alkaloid
present in fraction 3, which corresponds to Rt from 15.75 – 18.25 min of crude
extract chromatogram.
Fraction 3 contains three alkaloids (Figure 2.5 a.), of which only peak 10 from
fraction 2 (veratramine), corresponds to peak 1 in Fraction 3 (Figure 2.5 b.) with m/z
ratios of 410.2828 and 410.3057 respectively. The elution time for this alkaloid is
consistent between fractions at 17.6 min, lending further support for the identification.
Figure 2.5 c. shows peak 2 with an m/z of 412.3216, elution time of 18.4 min, and
predicted molecular formula C27H41NO2, which was confirmed to be cyclopamine.
Figure 2.5 d. displays peak 3 with an m/z of 412.3206, elution time of 18.9 min, and a
predicted molecular formula of C27H41NO2 (predicted to be cyclopamine’s isomer42).
Figure 2.6 displays the six detected alkaloids found in fraction 4.
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Figure 2.6
Chromatogram and extracted ion chromatogram for each alkaloid
present in fraction 4, which corresponds to Rt from 18.25 – 20.75 min of crude
extract chromatogram.
In Figure 2.6 a. there are six alkaloids present. Figure 2.6 b. shows peak 1 with
m/z 412.2996, elution time 18.4 min, and predicted molecular formula C27H41NO2
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consistent with cyclopamine. Figure 2.6 c. displays peak 2 with an m/z of 410.2815,
elution time of 18.8 minutes, and predicted molecular formula of C27H39NO2. This may
be an isomer of veratramine. Peak 3 as seen in Figure 2.6 d. has an m/z of 412.2971, an
elution time of 18.9, and a predicted molecular formula of C27H41NO2. This is potentially
an isomer of cyclopamine.42 Figure 2.6 e. contains peak 4 which has an m/z of 474.3293,
elution time of 19.2 min, and predicted molecular formula of C29H47NO4 (identity
unknown). Peak 5 (Figure 2.6 f) has an m/z of 456.3208, an elution time of 19.4 min,
and a predicted molecular formula of C29H45NO3 (identity unknown). Lastly, peak 6
(Figure 2.6 g) has an m/z of 458.3368, an elution time of 19.8 min, and a predicted
molecular formula of C29H47NO3, which is consistent with muldamine71.
Within the final fraction eight different compounds were noted. Figure 2.7 shows
the HPLC chromatogram for fraction 5 as well as the corresponding mass spectrum for
each alkaloid peak.
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Figure 2.7
Chromatogram and extracted ion chromatogram for each alkaloid
present in fraction 5, which corresponds to Rt from 20.75 – 23.25 min of crude
extract chromatogram.
Figure 2.7 a. shows the eight alkaloids present in the chromatogram for fraction
5. Peak 1 (Fig. 2.7 b.) has an m/z of 412.2931, an elution time of 18.5 min, and a
predicted molecular formula of C27H41NO2, again corresponding to cyclopamine. Figure
2.7 c. displays peak 2 with an m/z of 474.3302, an elution time of 19.2 min, and a
predicted molecular formula of C29H47NO4. This is consistent with peak 4 from fraction 4
(Figure 2.6 e.), which has an unknown identity. Peak 3 (Figure 2.7 d.) has an m/z of
456.3214, an elution time of 19.4 min, and a predicted molecular formula of C29H45NO3,
which matches peak 5 from fraction 4 (Figure 2.6 f.), but has an unknown identity. Peak
4 (Figure 2.7 e.) has an m/z of 416.3273, an elution time of 19.6 min, and a predicted
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molecular formula of C27H45NO2, which has a suspected identity of 22-keto-26aminocholesterol71. Figure 2.7 f. contains peak 5 with an m/z of 458.3381, an elution
time of 19.8 min, and a predicted molecular formula of C29H47NO3. This peak matches
peak 6 from fraction 4 (Figure 2.6 g.), which was predicted to be muldamine. Peak 6
(Figure 2.7 g.) has an m/z of 416.3286, an elution time of 20.0 min, and a predicted
molecular formula of C27H45NO2. This predicted molecular formula is the same as that of
peak 4 (Figure 2.7 e.) which is consistent with that of 22-keto-26-aminocholesterol71.
Figure 2.7 h. has peak 7 with an m/z of 398.3171, an elution time of 20.3 min, and a
predicted molecular formula of C27H43NO, which is consistent with verazine71. The final
peak, peak 8 (Figure 2.7 i.), has an m/z of 458.3354, an elution time of 20.5 min, and a
predicted molecular formula of C29H47NO3, which is representative of an isomer of
muldamine.
Twenty-five unique compounds were detected across the five fractions with nine
compounds repeated across more than one fraction and sixteen compounds found within
only a single fraction. The presence of veratramine and cyclopamine was confirmed
using the elution times of standards (Figure 2.9), and the identities of sixteen alkaloids
were suspected, leaving seven unknown. Table 2.1 demonstrates these findings.
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Table 2.1
extract
Rt

Summary of findings from five fractions of Veratrum californicum

m/z Molecular Formula

Identity

Fraction

Veratrosine

1

15.3

572.3

C33H49NO7

15.7

574.3

C33H51NO7

Cycloposine

1,2

16

572.3

C33H49NO7

Isomer of veratrosine*

1,2

16.1

576.4

C33H53NO7

?

2

16.2

430.3

C27H43NO3

Tetrahydrojervine*

2

16.5

574.3

C33H51NO7

Isomer of cycloposine*

1,2

16.6

618.4

C35H55NO8

?

2

16.9

578.4

C33H55NO7

?

2

17.1

428.3

C27H41NO3

Dihydrojervine* **

2

17.2

472.3

C29H45NO4

?

2

17.3

620.4

C35H57NO8

?

2

17.4

414.3

C27H43NO2

Etioline* **

2

17.5

428.3

C27H41NO3

Isomer of dihydrojervine* **

2

17.6

410.3

C27H39NO2

Veratramine

2,3

18.4/18.5 412.3

C27H41NO2

Cyclopamine

3,4,5

18.8

410.3

C27H39NO2

Isomer of veratramine*

4

18.9

412.3

C27H41NO2

Isomer of cyclopamine*

3,4

19.2

474.3

C29H47NO4

?

4,5

19.4

456.3

C29H45NO3

?

4,5

19.6

416.3

C27H45NO2

22-keto-26-aminocholesterol*

5

19.5

414.3

C27H43NO2

Isorubijervine**

4

19.8

458.3

C29H47NO3

Muldamine

4,5

20

416.3

C27H45NO2

Isomer of 22-keto-26-aminocholesterol*

5

20.3

398.3

C27H43NO

Verazine*

5

20.5

458.3

C29H47NO3

Isomer of muldamine*

5

*Signifies a prediction based on the m/z and molecular formula, but it has not
been confirmed in Table 2.1
**See Figure 2.8 for data
There were several alkaloids previously identified in V. californicum that did not
have a corresponding peak in any of the UV chromatograms including etioline,
dihydrojervine, and isorubijervine. These compounds were identified by retention time
and m/z ratios corresponding to data from prior reports.71 The results are shown in
Figure 2.8.
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Figure 2.8

Extracted ion chromatograms previously identified alkaloids present
in fractions 2 and 4 of crude alkaloid extract.

Figure 2.8 contains the alkaloids missing from the V. californicum extract as
described in the literature.71 The peak seen in Figure 2.8 a. has an m/z of 428.2899, an
elution time of 17.1 min (fraction 2), and a predicted molecular formula of C27H41NO3,
representing dihydrojervine. Figure 2.8 b. shows a peak with an m/z of 414.3113, an
elution time of 17.4 min (fraction 2), and a predicted molecular formula of C27H43NO2
corresponding to etioline. The peak seen in Figure 2.8 c. has an m/z of 428.2897, an
elution time of 17.5 min (fraction 2), and a predicted molecular formula of C27H41NO3,
which is consistent with dihydrojervine, and is thus assumed to be an isomer. The final
peak in Figure 2.8 d. has an m/z of 414.3105, an elution time of 19.5 min (fraction 4),
and a predicted molecular formula of C27H43NO2, which is isorubijervine.
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Figure 2.9 shows two peaks from the standard made of 355 µM veratramine and
390 nM cyclopamine.

Figure 2.9

Chromatogram and extracted ion chromatogram for 355 µM
veratramine and 390 nM cyclopamine.

Two peaks are seen in Figure 2.9 a. The peak in Figure 2.9 b. has an m/z of
410.2823, an elution time of 17.6 min, and a predicted molecular formula of C27H39NO2,
confirming its identity of veratramine. Figure 2.9 c. has an m/z of 412.2963, an elution
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time of 18.4 min, and a predicted molecular formula of C27H41NO2, verifying the
presence of cyclopamine.
Discussion
The chromatogram representing alkaloids extracted from V. californicum root and
rhizome that served as the basis for the present thesis is shown in Figure 2.1. There is
good correlation between these results and those most recently appearing in literature.71
This validated that the modified extraction method, using 25 g of plant material in 50.0
mL of 95% ethanol instead of 2 g in 100 mL, was effective at removing similar alkaloid
content from the roots and rhizomes of V. californicum as the work previously
performed.42 The fraction collection at intervals of 150 seconds, beginning at 10.25 min,
was intended to assess the alkaloids with the most desirable bioactivity from within the
crude extract (Figure 2.1). The region of the chromatogram based on the published
HPLC protocol, was selected based on the presence of alkaloids with suspected Hh signal
suppression activity, leading to the selection of fraction collection across the range of
10.25-23.75 min.74 Chromatograms for the five fractions collected over the 10.25-23.75
min crude extract (Figure 2.2 b-f) confirmed the presence of alkaloids separated into
smaller buckets that could be pursued for bioactivity characteristics.
Examination of chromatograms corresponding to fractions 1-5 (Figures 2.3-2.8),
show that fraction 1 contained four alkaloids, fraction 2 contained thirteen (including
those from Figure 2.8), fraction 3 contained three, fraction 4 contained seven (including
one from Figure 2.8), and fraction 5 contained eight. Veratrosine, cycloposine and their
isomers were identified in fraction 1 (Figure 2.3). Fraction 2 was made up of cyloposine,
its isomer, veratrosine’s isomer, tetrahydrojervine, dihydrojervine, its isomer, etioline,
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and veratramine, and five unknown alkaloids (Figures 2.4 and 2.8). Fraction 3 did not
have any compounds in it that were not found in other fractions. The presence of
veratramine and cyclopamine were confirmed by elution times of veratramine and
cyclopamine standards, and an isomer of cyclopamine was detected as well (Figures 2.5
and 2.9). Fraction 4’s only unique compounds were isorubijervine and an isomer of
veratramine, and it too included cyclopamine and its isomer, as well as muldamine, and
two unknown compounds (Figures 2.6 and 2.8). Lastly, Fraction 5 was made up of
cyclopamine, muldamine and its isomer, 22-keto-26-aminocholesterol and its isomer,
verazine, and two unknown compounds (Figure 2.7).71 This data is found summarized in
Table 2.1.
When examining the m/z ratios of the standards for veratramine and cyclopamine,
they were found to be 410.2823 and 412.2963 respectively (Figure 2.9), but the expected
m/z ratios were about 55 parts per million (ppm) lower than those values. This was likely
due to the sample concentration exceeding the limit of detection, and thus all the
molecular formulas were generated with a margin of error within the range of 54.5-61.8
ppm. Fraction 3 was an exception, as it was diluted by an additional order of magnitude,
resulting in an error of less than one ppm for veratramine and less than 2 ppm for
cyclopamine.
Table 2.1 confirms a lack in knowledge of the alkaloid content present in V.
californicum. Further work should be done to identify the detected alkaloids and pursue
the compounds with notable bioactivity. The plant roots and rhizomes used in this
experiment were gathered from the Shindig Trail (N43 45.719” W 116 05.327”) on July,
3, 2014. The chromatograms fitting this same description from Turner et al. 2019, did not
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detect the presence of etioline or dihydrojervine, and only a small peak for
isorubijervine.71 The missing alkaloids of etioline, dihydrojervine, and isorubijervine
(Figure 2.8) may not be detected sufficiently well by UV-Vis and may require detection
by CAD or MS.
Materials and Methods
Plant Material
Plants were harvested from the high mountain meadows of the Boise National
Forest, Idaho by the Shindig Trail at 6901 feet elevation (N43 45.719” W 116 05.327”)
on July, 3, 2014. The roots/rhizomes were separated from the above ground plant parts
and transported to the laboratory on ice. The roots/rhizomes were cut into 2 cm pieces
and freeze dried for 14 hrs with a LabConco Freezone 4.5 freeze drying unit (Labconco
Corporation, Kansas City, MO, USA). The pieces were then stored in sealable plastic
bags at -20°C until use.
Extraction
Root/rhizome pieces were removed from the freezer, thawed, and cut to about 2
cm in size. They were frozen in liquid nitrogen followed by freeze drying a second time
for 24-48 hours using a LabConco Freezone 4.5 freeze drying unit (Labconco
Corporation, Kansas City, MO, USA). A coffee grinder (Mr. Coffee, IDS77) was used to
create a fine powder, which was either used immediately or stored in a vacuum-sealed
bag in the freezer. A 50.0 mL volume of 95% ethanol was added to 25 g of powdered
plant material and the solution sonicated for 30 min. All solvents were purchased from
Fisher Scientific unless otherwise specified. This mixture was stirred overnight on a stir
plate before vacuum filtration (Whatman filter paper, 0.45 µm). The solid plant material
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was discarded, and the ethanol was removed from the filtrate by rotary evaporation at
reduced pressure. The remaining solid was resuspended in 10.0 mL 95% ethanol, warmed
to 40°C, and sonicated for five minutes. Ammonium hydroxide was added until the pH of
the solution exceeded 10. This solution was then added to a supported liquid extraction
(SLE) column (Chem Elut, Agilent, Santa Clara, CA, USA or HyperSep SLE,
ThermoFisher Scientific, Pittsburgh, PA, USA) and allowed to absorb for 10 min.
Alkaloids were eluted with chloroform (3 x 10 mL) using a vacuum manifold. The
combined chloroform fractions were dried using rotary evaporation, and the alkaloids
were dissolved in 1.0 mL of 100% ethanol.
Separation
For the preliminary examination of the extract and fraction collection a Dionex
UltiMate® 3000 uHPLC system coupled to a DAD and an automated fraction collector
was used. Separation was performed using a semi-preparative Agilent Zorbax SB-C18
column (9.4 x 250 mm, 5 µm) with mobile phases of 0.1% trifluoroacetic acid (TFA) in
water (Buffer A) and HPLC grade acetonitrile (Buffer B). The flow rate was set to 3.0
mL/min starting with 15% Buffer B with a linear gradient up to 60% Buffer B for 25
minutes. From 25.1 minutes to 30 minutes Buffer B was set to 15%. Five fractions were
collected starting at 10.75 minutes in 150 sec intervals. Fractions of the same retention
times were pooled, evaporated to dryness by rotary evaporation, and resuspended in 2.0
mL of 100% ethanol. Fractions 1-5 were stored at -20 °C until they could be analyzed by
LC-MS.
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Identification
The raw extract and fractions were examined using a Thermo Scientific UltiMate
3000 HPLC paired with a Corona Veo RS CAD. A Thermo Acclaim 120 C18 column (2.1
x 150 mm, 3 µm) with mobile phases of 0.1% (TFA) in water (Buffer A) and acetonitrile
(Buffer B) was used. The flow rate was set to 0.3 mL/min starting with 15% Buffer B
with a linear gradient up to 60% Buffer B for 25 minutes. From 25.1 minutes to 30
minutes 15% Buffer B was used. Standards for cyclopamine (10.1 mM) and veratramine
(10.1 mM) were run using the same method in order to compare elution times.
To more precisely identify the alkaloids present, LC-MS analysis was performed
using an ultra-high resolution Quadrupole Time of Flight (QTOF) instrument (Bruker
maXis). The electrospray ionization (ESI) source was operated under the following
conditions: positive ion mode, 1.2 bar nebulizer pressure, 8 L/min flow of N2 drying gas
heated to a temperature of 200 °C, 3000 V to -500 V voltage between HV capillary and
HV end-plate offset, mass range set from 80 to 800 m/z, and the quadrupole ion energy at
4.0 eV. Sodium formate was used to calibrate the system in the mass range of 80 to 800
m/z. HPLC separation was achieved using an XTerra MS C18 column, 3.5 μm, 2.1 x 150
mm (Waters, Milford, MA, USA). The flow rate was set to 200 μL/min. The mobile
phases were 5% acetonitrile and 0.1% formic acid in water (Buffer A) and acetonitrile
and 0.1% formic acid (Buffer B). The linear gradient method was used to separate
analytes starting at 5% Buffer B and increasing to 70% Buffer B over 25 min. A 1 μL
sample injection was used. The data was analyzed with the Compass Data Analysis
software package (Bruker Corporation, Billerica, MA, USA).
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Chemicals and Solvents
The cyclopamine standard (>99% purity) was purchased from Alfa Aesar (Ward
Hill, MA, USA), and the veratramine standard (>98.0% purity) was from Tokyo
Chemical Industry (TCI) (Tokyo, Japan). The extraction solvents 95% ethanol,
ammonium hydroxide, and chloroform were purchased from Fisher Scientific
(Pittsburgh, PA, USA), and the 100% ethanol was from Decon Labs (King of Prussia,
PA, USA). The HPLC mobile phases TFA and acetonitrile (>99% purity) were also
obtained from Fisher Scientific.
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CHAPTER THREE: BIOACTIVITY ANALYSIS OF VERATRUM CALIFORNICUM
EXTRACTED ALKALOID COMBINATIONS
Introduction
The Hedgehog (Hh) signaling pathway is one of the most important signaling
pathways, and it is one of a small number that is active for intercellular communication
during development.52,85 It plays a crucial role for proper formation of vertebrate embryos
in regards to bilateral symmetry, the central nervous system, skeleton, limbs, teeth, eyes,
and several vital organs.52,86 When there is loss of proper function of this pathway the
results can range from under-developed facial features to cyclopia to nervous system
disorders.86
The Hh gene was first discovered in the Nobel prize-awarded work in 1978
during the gene knockout trials in Drosophila by Christiane Nusslein-Volhard and Eric
Wieschaus. The fruit fly embryo resembled a hedgehog with a short body and spine-like
projections when the Hh gene was silenced. 86,111 The vertebrate Hh pathway is
dependent upon three signaling molecules: Desert hedgehog (Dhh), Indian hedgehog
(Ihh), and Sonic hedgehog (Shh), which get their names from two hedgehog breeds and a
fictional character.86 In humans, when Shh protein binds Patched 1 (PTCH), a 12-span
transmembrane protein, a seven-span transmembrane protein, Smoothened (Smo),
initiates a signaling cascade. The levels of zinc-finger transcription factors from the Ci
(cubitus interruptus)/Gli family determines if the Hh signal is transmitted. Gli 1 and Gli 2
function as activators while Gli 3 is a repressor. Gli 1 is directly connected to Hh
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pathway activation that its function is monitored to determine the activation state of the
signaling pathway. The teratogenic alkaloid cyclopamine was the first discovered Hh
pathway suppressor. Instead of PTCH binding to Smo as an inhibitor, cyclopamine takes
PTCH’s place, stopping signal transduction.85,86 Chris Chandler designed and created a
cell signaling image that can be seen in Figure 3.1.

Figure 3.1
The hedgehog signaling pathway, where the left side of the figure
represents when the pathway is off due to PTCH inhibiting SMO, and the right side
represents when the pathway is activated by Hh protein binding to PTCH allowing
SMO to function
Once most cells have matured, the Hh signaling pathway is no longer in use, but
its aberrant activation is associated with the development of over twenty different types
of cancer.2,86 A promising realm of treatment of these cancers includes finding inhibitors
to block the pathway’s succession without the typical side effects of traditional methods,
which is usually done by targeting Smo and more recently Gli.48,86 In mouse models
cyclopamine has suppressed tumor growth for eight different types of cancer, and in
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humans it has been used in the form of a topical ointment applied directly to tumors,
leading to shrinkage of cancerous tissue without adverse side effects.86
There are some drawbacks with using cyclopamine as a chemotherapeutic: it has
little solubility in physiological conditions or water, it breaks down under acidic
conditions (such as in the presence of human stomach acid), and as some specific cell
types do still utilize the Hh pathway into maturity, it can have some off-target side
effects.48,71,86 The cyclopamine molecular scaffold has been used as a model for drug
development in therapeutics targeting the blockage of Hh pathway signaling. Initial drug
development efforts at Johns Hopkins University began by adding a 3-keto N(aminoethyl-aminocaproyl-dihydrocinnamoyl) moiety to cyclopamine (KAADcyclopamine). In mouse model studies, KAAD-cyclopamine exhibited inhibition levels
that exceeded cyclopamine by 10-20 fold.86 Improving solubility of cyclopamine does not
eliminate deleterious side effects. Another effort to develop a therapeutic resulted in IPI926, a compound based on alteration of native cyclopamine, making the natural product
more stable and potent. Phase 2 clinical trials with IPI-926 were aborted due to the
median survival rate for patients being less than that of the placebo group.86 Yet another
drug discovery pathway inspired by cyclopamine was pursued, but this time it was a
computational predictive approach to small molecule creation. One such high throughput
virtual screening workflow surveyed a high volume of small molecules for Smo
binding.112 In January of 2012 Vismodegib (GDC-0449 or Erivedge) was approved by
the FDA for treatment of metastatic basal cell carcinoma (mBCC) or locally advanced
basal cell carcinoma (laBCC) in adults that are ineligible for radiation therapy or
surgery.112,113 Created by Genentech, Inc., in phase II clinical trials Vismodegib had an
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overall response rate (ORR) of 60% for patients with laBCC and 46% for patients with
mBCC. 43% of patients with laBCC demonstrated significant tumor shrinkage or healed
lesions, and 30% of patients with mBCC noticed tumor shrinkage. The most common
side effects were: decreased appetite, diarrhea, dysgeusia, fatigue, hair loss, muscle
spasms, and nausea.112 Sonidegib (LDE225, erismodegib, or ODOMZO), also identified
in a small-molecule in vitro screening study, was designed by Sun Pharma Global and
approved by the FDA in 2015 for treatment of recurrent advanced basal cell carcinoma
(aBCC) or patients not suitable for radiation of surgery.48,114,115In Phase II clinical trials,
over 50% of patients taking 200 mg daily saw objective responses. 18 out of 94 patients
with laBCC either died or had their condition progress, but more than 50% had a
response for longer than 6 months. 80% of patients with mBCC maintained an objective
response. The most common to least common side effects when taking Sonidegib were:
muscle spasms, alopecia, dysgeusia, nausea, increased creatinine kinase, fatigue,
decreased weight, diarrhea, decreased appetite, myalgia, and vomiting.114 It has been
found that over time patients’ bodies have developed methods of resisting the inhibitory
properties of these two drugs. Sometimes Smo mutates, or an alternative Hh pathway
initiates.116 The most recent FDA-approved Hh signaling pathway inhibitor is Glasdegib
(PF-0449913 or DAURISMO™), which is an oral drug developed by Pfizer and approved
in 2018 for use in combination with low-dose cytarabine (LDAC) to treat acute myeloid
leukemia (AML) for patients ages 75 and older or those who have co-morbidities which
do not allow the use of intensive induction chemotherapy.48,117 The BRIGHT AML 1003
study showed a 54% reduction in mortality with glasdegib in combination with LDAC
compared to LDAC alone. Pneumonia, fatigue, dyspnea, hyponatremia, sepsis, and
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syncope were the most common side effects of using glasdegib with LDAC.117 Figure
3.2 shows the structures for each of the above mentioned modified alkaloids (KAADcyclopamine and IPI-926) and chemotherapeutics (vismodegib, sonidegib and glasdegib).

Figure 3.2
Structures of hedgehog signaling pathway inhibitors cyclopamine,
modified forms of cyclopamine, and computationally derived, FDA approved
chemotherapeutics
Cyclopamine was the first discovered inhibitor of the Hh pathway, and many
derivatives of it have improved function to suppress Hh signaling, so it is logical to return
to the plant source in search of additional Hh signaling suppressors that may have been
missed at time of the original work in the 1950’s. It took until 1968, for cyclopamine to
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be extracted from the native Idaho plant Veratrum californicum and finally
characterized.86 The plant was initially noticed when it was determined to be the cause of
cyclopic malformations in newborn lambs in central and southern Idaho.86,103 Pregnant
ewes fed on the plant, which contained toxic alkaloids with the ability to block the Hh
pathway, leading to malformed embyos.2,86
Preliminary work has been done in our lab demonstrating that a raw alkaloid
extract has more potent inhibitory effects on the Hh signaling pathway than cyclopamine
alone at commensurate concentration.42,71 This preliminary study result motivated the
current investigation. Five fractions of alkaloids were collected from the raw extract
chromatogram using HPLC-DAD and an automated fraction collector based on elution
time. A cyclopamine standard, the raw extract, and the five fractions were then tested for
bioactivity using a Shh-Light II cell line obtained from Johns Hopkins University, in
order to measure Gli activity. It was found that three of the fractions had a statistically
significant enhanced potency to suppress Hh signaling as compared to cyclopamine
standard. Further separation and isolation of V. californicum alkaloids contained within
fractions 1, 2 and 4 constitutes a worthy pursuit for discovery of cancer therapeutics.
Results
The bioactivity of the Shh-Light II cell line was measured using the DualLuciferase® Reporter Assay System.118 Shh protein was added in order to activate the
pathway and trigger an increase in the presence of Gli transcription factors, which was
detected as luminescence by a plate reader.85,86 Each 96-well plate contained three wells
with each of the following treatments: negative controls (media only), positive controls
(media and Shh protein), and treatments consisting of 0.1 µM cyclopamine, 0.01 or 0.05
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µM cyclopamine, 1:200 dilutions of raw alkaloid extract, 1:1000 dilutions of raw alkaloid
extract, 1:20 dilutions of each fraction, and 1:100 dilutions of each fraction in media with
added Shh protein. The results of this assessment for four plates (a total of 12 wells for
each treatment), is shown in Figure 3.3 a-b. along with a detailed view of all high
concentration treatments.
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Figure 3.3
Results from bioactivity assessment of cyclopamine, raw extract, and
five fractions. a. Both high (1:200 dilution for extract and 1:20 dilution for fractions)
and low (1:1000 dilution for extract and 1:100 dilution for fractions) concentrations
of each treatment. b. Only high concentrations of each treatment, where * signifies P
< 0.05 and ** signifies P < 0.01 as compared to 0.1 µM cyclopamine.
Figure 3.3 a shows that for every individual treatment, the higher concentration
always showed greater Gli-reporter inhibition than the lower concentration. In addition,
none of the low concentration treatments were more potent than the high concentration of
cyclopamine standard. For Figure 3.3 b cyclopamine (final concentration of 0.1 µM) had
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relative Gli-reporter activity of 63.56 ± 18.40, while fraction 1 was 1.376 ± 8.231,
fraction 2 was 12.04 ± 11.66, and fraction 4 was 17.73 ± 9.10. Fraction 1 was
significantly more suppressive of the Hh signaling pathway than cyclopamine (P<0.01)
as were fractions 2 and 4 (P<0.05).
Table 3.1

Summary of MS data for Fractions 1 (blue), 2 (purple), and 4 (pink)

Table 3.1 shows a summary of the MS data presented in Chapter 2 for fractions 1,
2, and 4. Fraction 1 contained four alkaloids hypothesized to be veratrosine, cycloposine,
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and an isomer of each. Fraction 2 had 10 identified compounds: cycloposine, its isomer,
the isomer of veratrosine, and tetrahydrojervine are all suspected to be present,
veratramine was confirmed, and five molecules remain unknown. Cyclopamine has a
verified presence within fraction 4, and its isomer, the isomer of veratramine, and
muldamine are all suspected to be present, along with two unknown compounds.
Discussion
The data tabulated in Table 3.1 identifies the compounds present in each alkaloid
fraction that demonstrate better activity at Gli-reporter inhibition than cyclopamine.
Fraction 1 demonstrated the best Gli-reporter suppression, with only four alkaloids,
cycloposine, veratrosine, and their isomers. While the activity of cycloposine and
veratrosine has been determined to be lower than cyclopamine, little is known about the
activity of their isomers.74 With regard to fraction 2, there were at least thirteen different
alkaloids, including veratramine, a known Hh signaling inhibitor, and it was not nearly as
potent. Fraction 2 also contained every alkaloid present within fraction 1 except for
veratrosine. Figure 3.4 shows the relative concentrations of fractions 1, 2, and 4
compared to 0.1 µM cyclopamine as derived from the areas of the relevant alkaloid peaks
in the total ion chromatograms. Fraction 4 contained an abundance of cyclopamine, but
despite that, it too was not as effective as fraction 1. Cyclopamine was found to be
present across three of the five fractions collected from the extract, so the cyclopamine
concentration in any give fraction may have been low. Fraction 4 contained six alkaloids
in addition to cyclopamine, including muldamine, which does not have a well-defined Hh
signaling effect.

71

Figure 3.4

Relative concentrations of fractions 1, 2, and 4 as compared to 0.1 µM
cyclopamine.

Figure 3.4 a shows that the sum of the relevant alkaloid content within individual
fractions 1, 2, and 4 exceeds that of 0.1 µM cyclopamine. Cyclopamine has already been
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established as having the greatest Hh pathway suppression of any alkaloid within V.
californicum.74 In fraction 1, veratrosine and cycloposine are ineffective in this regard,
and thus their isomers at must be contributing to the Hh signaling inhibition.74 Figure 3.4
b shows the isomers’ relative content is 5.65 x 105 for the isomer of veratrosine and 1.31
x 106 for the isomer of cycloposine. The isomer of veratrosine had an m/z of 572.3, an
elution time of 16.0 minutes, and a predicted molecular formula of C33H49NO7. The
isomer of cycloposine had an m/z of 574.3, an elution time of 16.5 min, and a predicted
molecular formula of C33H51NO7. Based upon their low, relative concentration within
fraction 1, and fraction 1 being the most potent, these two alkaloids are most worthy of
pursuit for further characterization.
Materials and Methods
See Materials and Methods section of Chapter 2.
Cell Culture
Shh-Light II cells were grown and maintained in Dulbecco’s Modified Eagle
Medium (DMEM) (Gibco) with added geneticin (0.4 mg/mL), Zeocin™ (0.15 mg/mL
from Invitrogen), 10% fetal bovine serum (FBS), and 1% penicillin-streptomycin. The
conditions for cell growth were as follows: 37 °C, atmosphere of 5% CO2, and 100%
relative humidity. The Dual-Luciferase® Reporter Assay System was used on four
different plates. The cells for first three plates were all generated from the same stock,
where the first was passaged five times, the second eight times, and the third eleven
times, and the fourth plate’s cells were generated from a different cell stock that had been
passaged twice. 10,000 cells in 100 µL growth media were added to each well of the 96well plate and allowed to grow to at least 80% confluency before the media was swapped
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for DMEM with added 0.5% FBS, 0.5% penicillin-streptomycin, and 2.5-5.0 µg Nterminal mouse recombinant Shh (R&D Systems, Minneapolis, MN, USA). Each control
and treated well contained a final concentration of 1% ethanol. Forty eight hours after
treatment, Gli activity was assayed using the Dual-Luciferase® Reporter Assay System
(Promega, Madison, WI, USA) by measuring the luminescence from the cells with a
BioTek Synergy H1m Microplate reader. In order to induce luminescence the cells were
first lysed, then 100 µL of Luciferase Assay Substrate in Luciferase Assay Buffer II
(LAR II) was added to each well, and the firefly luciferase luminescence measurement
was recorded. Then 100 µL of Stop & Glo® Substrate in Stop & Glo® Buffer (Stop &
Glo® Reagent) was dispensed into each well and the Renilla luciferase luminescence was
measured. The relative response ratio (RRR) was calculated as described in the DualLuciferase® Reporter Assay System manual in order to display the results. Each
experiment was performed in triplicate across four plates for a total of 12 trials.
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CHAPTER FOUR: CONCLUSION AND FUTURE DIRECTIONS
In the pursuit of more effective and on-target cancer therapeutics, the alkaloids
contained within V. californicum are worthy of natural product drug discovery
investigation. Currently, there are six alkaloids that have been identified and
characterized, twelve suspected, and at least seven alkaloids that have been detected, but
remain to be identified from the root and rhizome extract of V. californicum. Based off of
the literature some additional predictions can be made concerning the identities of the
seven detected alkaloids marked with question marks in Table 2.1.
The alkaloid detected at 16.1 minutes in fraction 2 with a predicted molecular
formula of C33H53NO7 may be isorubijervosine. It has been previously extracted from V.
eschscholtzii.39 Isorubijervosine is the glycosylated version of isorubijervine, one of the
six known alkaloids in V. californicum.71 The glycosylated versions of cyclopamine and
veratramine (cycloposine and veratrosine) also have a confirmed presence within V.
californicum, lending further support to this prediction.71 No hedgehog signaling
bioactivity assessments of this molecule have been reported in the literature.
At 16.6 minutes, also within fraction 2, an alkaloid with the predicted molecular
formula C35H55NO8 was detected. Isoveralosine matches the molecular formula and has
been previously identified within V. grandiflorum119 and V. lobelianum120. It has been
tested for hedgehog signaling activity using the same Shh-Light II cell line and DualLuciferase® Reporter Assay, but was found to be inactive.119
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A molecule was detected at 16.9 minutes in fraction 2 with a predicted molecular
formula of C33H55NO7. This is consistent with the molecular formula for Stenophylline B
3-O-β-D-glucopyranoside, which has been previously extracted from V. taliense.121,122 It
has demonstrated antifungal activity, but no work has been done concerning the
hedgehog signaling pathway.122
At 17.2 minutes within fraction 2, an alkaloid was detected with the predicted
molecular formula C29H45NO4. This is thought to be (20R,25R)-12b-O-acetyl-20βhydroxyisoverazine, which has been previously extracted from V. grandiflorum.119 Using
the same Shh-Light II cell line and Dual- Luciferase® Reporter Assay as described
previously, it showed suppression of hedgehog signaling.119
The last unknown alkaloid found within fraction 2 was reported at 17.3 minutes
and has a predicted molecular formula of C35H57NO8. (3β,5α,16α,20S)-16-(acetyloxy)20-[(5S)-3,4,5,6-tetrahydro-5-methyl-2-pyridinyl]-β-D-glucopyranoside has the same
molecular formula, but it has not been previously identified within the Veratrum genus. It
has been extracted from Solanum pseudoquina, and it has unknown activity in relation to
the hedgehog signaling pathway.123
The alkaloid detected at 19.2 minutes within fraction 4 has the predicted
molecular formula C29H47NO4. The molecule baikeidine has the same formula and has
been identified within V. grandiflorum. The bioactivity has not been tested for this
alkaloid.124
Lastly, at 19.4 minutes in fraction 4 a molecule was extracted with the predicted
molecular formula C29H45NO3. Veralosinine has the same molecular formula and has
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been identified in V. lobelianum. It has demonstrated favorable inhibition of multidrug
resistance, but has not been tested for hedgehog signaling inhibition.125
The crude extract of V. californicum, when separated by time into five fractions,
provides bioactivity efficacy superior to 0.1 µM cyclopamine alone for fractions 1, 2, and
4. The alkaloid composition of these fractions consists of between four and thirteen
components. Bioactivity testing of isolated alkaloids from fractions 1, 2, and 4 constitute
the logical next step to measure performance with the Shh-Light II cell line, followed by
subsequent testing of the most potent Hh suppressors in BCC cells. The most effective
inhibitors would need to be isolated in sufficient quantity to be characterized by nuclear
resonance spectroscopy in order to determine their molecular structure. Any newly
characterized alkaloids have the potential to be vetted as chemotherapeutics or precursors
to chemotherapeutics for cancers involving Hh signaling.
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APPENDIX A
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Figure A.1

Figure S1. Structures of Veratrum spp. steroidal alkaloids, excluding
those found in V. californicum1
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APPENDIX B
Further Assessment of Bioactive Alkaloids from Veratrum californicum found in
Table 1.4
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Figure B.1

Data on Cyclopamine from SwissADME 126
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Figure B.2

Data on Veratramine from SwissADME 126
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Figure B.3

Data on Isorubijervine from SwissADME 126
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Figure B.4

Data on Muldamine from SwissADME 126
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Figure B.5

Data on Verazine from SwissADME 126
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Figure B.6

Data on Etioline from SwissADME 126
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Figure B.7

Data on Dihydrojervine from SwissADME 126

